Navigation Links
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Date:9/3/2007

0.001).

The study also showed both treatment arms to yield similarly low rates of mortality and myocardial infarction. The mortality rates were 8.6 percent for the CYPHER(R) Stent and 7.9 percent for the bare metal stent (p=0.850), the Q- wave myocardial infarction rate for each treatment arm was 1.1 percent (p=1.00) and the non-Q-wave myocardial infarction rates were 7.4 percent for the CYPHER(R) Stent and 5.1 percent for the bare metal stent (p=0.388).

Also importantly, the study did not find a significant difference in the rates of stent thrombosis between the CYPHER(R) Stent and the bare metal stent, regardless of whether protocol or Academic Research Consortium (ARC) definitions were employed. When the protocol definitions were used, the rates of acute and subacute stent thrombosis were 0.0 percent for the bare metal stent and 1.1 percent for the CYPHER(R) Stent (p=0.25). The late stent thrombosis rates were 0.0 percent for the bare metal stent and 1.7 percent for the CYPHER(R) Stent (p=0.12). The definite/probable ARC definition identified a stent thrombosis rate of 4.2 percent for the CYPHER(R) Stent versus 1.7 percent for the bare metal stent (p=0.199). The definite/probable/possible ARC definition yielded a stent thrombosis rate of 6.5 percent for the CYPHER(R) Stent versus 3.5 percent for the bare metal stent (p=0.216). While there were numeric differences in the timing of such events between the CYPHER(R) Stent and the bare metal stent, at no point throughout the five-year period were the differences statistically significant.

"The results presented today reaffirm the long-term clinical benefits of the CYPHER(R) Stent compared to bare metal stents," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "As previously announced, Cordis is expanding the E-SIRIUS Trial to eight years of follow-up to provide physicians with longer term data about the CYPHER(R) Stent that will assist them in making inf
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
3. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
4. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
5. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014 ... industry leader in bioactive lipid-targeted therapeutics, received official notification ... has been granted another key patent supporting its ... newly issued patent, European patent No. 2087002, claims ... substance in Lpath,s two lead compounds, iSONEP and ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/20/2014)... N.C., Oct. 20, 2014  BioPontis Alliance for ... both philanthropies, announced today the creation of a ... treatment of the rare disease known as Charcot- ... its alliance model earlier this month. Today,s partnership ... a collaborative model where researchers and all CMT ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... On July 31 , Massachusetts lawmakers passed legislation ... sentencing laws. , , , ... Drug offenders serving mandatory minimum sentences at county Houses of Correction will ... bill lawmakers voted on did not include two reforms previously endorsed by ...
... Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals ... a privately-held drug development company focused on liver disease and oncology. ... Conatus Pharmaceuticals ... of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The ...
Cached Medicine Technology:FAMM Applauds Massachusetts Legislature for Sentencing Reforms 2Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground on ... $11 million project will include the latest in Assisted ... full-service restaurant style dining. , “We are excited to ... Living apartments,” said Kara Hanzie, Rockynol Executive Director during ... care and this investment is proof of our commitment.” ...
(Date:10/20/2014)... 20, 2014 Final Cut Pro X Plugin ... the Citrus theme for FCPX filmmakers . , “Fun, ... describe the Citrus theme” Says Christina Austin, CEO of Pixel ... so professional.” , Citrus comes with all the tools needed ... are: four transitions for added style, a title screen for ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most ... range of bamboo deckings . Moreover, the company ... they are now available at deeply discounted rates. ... hard to overstate the significance of online business nowadays. ... services. The company’s workers are striving to deliver both ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... Leading Researchers to Discuss, State of Breast Cancer ... BOSTON, April 9 The Massachusetts Affiliate of Susan ... 10 at Harvard Medical,School, featuring some of the nation,s ... recent advances in breast,cancer research and the need for ...
... April 9, 2008 A company founded by an,industry ... and Canada sales,and distribution outlet for the Japanese "Paro" ... (ISC) of Japan, announced,today at the RoboBusiness Conference & ... Inc., founded by Walter Weisel, began its development,through a ...
... global clinical,research organization, is pleased to announce that it ... CRO,s in Las Vegas, Nevada from April,14 to the ... of its executive team and employees. Chiltern will be ... at 2:45 pm -- Track: Relationship Management Resource ...
... suggests that a genetic fingerprint associated with normal embryonic ... function of cancer stem cells. The research, published by ... Stem Cell, demonstrates that embryonic stem cells and multiple ... pattern that is repressed in normal differentiated cells, a ...
... ability to stabilize blood-brain barrier may play role in ... A little caffeine every day could offer some protection ... , Rabbits given the daily caffeine equivalent of one ... 12 weeks suffered relatively little damage in their blood-brain ...
... (MDC), a privately-owned chain of dental clinics in ... Dental Center, has reached,a settlement with the United ... allegations, the Justice Department announced today. Under the,agreement, ... that it,caused false or fraudulent claims for payment ...
Cached Medicine News:Health News:Massachusetts Affiliate of Susan G. Komen for the Cure to Spotlight Gaps in Breast Cancer Research 2Health News:'Paro,' the Baby Seal Service Robot From Japan, Finds a New Home in the United States With Help From JETRO 2Health News:Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008. 2Health News:Module map links embryonic stem cells and cancer stem cells 2Health News:Caffeine May Block High Cholesterol Linked to Alzheimer's 2Health News:North Carolina Dental Services Chain Pays $10 Million to Resolve False Claims Allegations 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: